These results suggest that the anti-ZSCAN1 autoantibody level is a feasible diagnostic marker in patients with ROHHAD syndrome not accompanied by a tumor. This evidence concerns the gene ZSCAN1 and rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome.